DOCSLIB.ORG

(12) United States Patent (10) Patent N0.: US 8,729,070 B2 Glozman (45) Date of Patent: May 20, 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent N0.: US 8,729,070 B2 Glozman (45) Date of Patent: May 20, 2014 US008729070B2 (12) United States Patent (10) Patent N0.: US 8,729,070 B2 Glozman (45) Date of Patent: May 20, 2014 (54) CNS PHARMACEUTICAL COMPOSITIONS FOREIGN PATENT DOCUMENTS AND METHODS OF USE GB 2 I66 651 5/1986 (75) Inventor: Sabina Glozman, Naharya (IL) OTHER PUBLICATIONS (73) Assignee: Targia Pharmaceuticals, Jerusalem (IL) Ashton H, Toxicity and adverse consequences of benzodiazepine use, ( * ) Notice: Subject to any disclaimer, the term of this Psychiatric Annals, 1995;25: 15 8-65 .* Eccles, Substitution of phenylephrine for pseudoephedrine as a nasal patent is extended or adjusted under 35 decongestant. An illogical way to control metamphetamine abuse. U.S.C. 154(b) by 468 days. British Journal ofClinical Pharmacology, 63:1, pp. 10-14, published online Nov. 20, 2006* (21) Appl.No.: 12/860,846 European Search Report for corresponding European Patent Appli cation No. 097115679 dated Jan. 18,2012. (22) Filed: Aug. 20, 2010 International Search Report for corresponding PCT Application No. PCT/IB2009/000309 dated Jul. 27, 2009. (65) Prior Publication Data Written Opinion of the International Searching Authority for corre US 2011/0054038 A1 Mar. 3, 2011 sponding PCT Application No. PCT/IB2009/000309 dated Jul. 27, 2009. International Preliminary Report on Patentability for corresponding Related US. Application Data PCT Application No. PCT/IB2009/000309 dated Aug. 24, 2010. (63) Continuation-in-part of application No. PCT/IB2009/000309, ?led on Feb. 20, 2009. * cited by examiner (60) Provisional application No. 61/030,141, ?led on Feb. 20,2008. Primary Examiner * Sreeni Padmanabhan Assistant Examiner * Svetlana M Ivanova (51) Int. Cl. (74) Attorney, Agent, or Firm * Rodney J. Fuller; Booth A61K31/55 (2006.01) Udall Fuller, PLC A61K31/155 (2006.01) A61K33/30 (2006.01) (57) ABSTRACT A61K31/19 (2006.01) (52) U.S.Cl. The present invention is directed to CNS pharmaceutical USPC ......... .. 514/220;514/221;514/635;514/718; compositions and methods of use. The pharmaceutical com 5 14/5 68 positions comprise a CNS active agent and preferably at least (58) Field of Classi?cation Search two vagal neuromodulators, one of which is a mechanorecep None tor stimulator. The vagal neuromodulators are preferably in See application ?le for complete search history. an amount su?icient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic ef?cacy/ (56) References Cited activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically U.S. PATENT DOCUMENTS comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and 6,833,377 B2 * 12/2004 Serdyuk ...................... .. 514/327 administration of at least two vagal neuromodulators to the 2002/0015713 A1 2/2002 Murdock et a1. 2004/0063628 A1 4/2004 Piccariello et al. patient so that at least one neuromodulator is administered or 2005/0008690 A1 1/2005 Miller released from dosage form after the CNS active agent is 2005/0031651 A1 2/2005 Gervais et al. administered and/or released. 2005/0267009 A1 12/2005 Deagle 2008/0020018 A1 1/2008 Moodley et al. 2009/0197958 A1 * 8/2009 Sastry et al. ................ .. 514/563 4 Claims, 7 Drawing Sheets U S. Patent May 20, 2014 Sheet 3 0f7 US 8,729,070 B2 Tablet AM Tabiet AM Tablet PM (white) (blue) (r052) Lurazepam GUA/PSE— Lurazepam » Day time": delayeck Bed time dusage immediate dcsage reiease US. Patent May 20, 2014 Sheet 4 0f7 US 8,729,070 B2 FIG. 4 US. Patent May 20, 2014 Sheet 5 0f7 US 8,729,070 B2 $354-$141? (1" 31% W15 imam 52:15 mm iii?f‘i wag "20:30 95 7%. 58 U! “My, Mililill¥ & “my may a “kw Lanai"; manna? m“ 4033: Yam Tang {0. 2"»; -+- 0:00;; new Tam Rama _ a: In mi.' 120130 aim/35??- ‘ H. US. Patent May 20, 2014 Sheet 6 0f 7 US 8,729,070 B2 aw“ mm“ w wwwm haw m3 wwwm mm“ wng um.“sz$333% céguwwx.“2%E ENE0 wwmwnw NEwa NinaI Ezmm 3%“$32anawawa“35a“ addMm,“ w. :3; ‘daagsv Qua; {moi US. Patent May 20, 2014 Sheet 7 0f 7 US 8,729,070 B2 US 8,729,070 B2 1 2 CNS PHARMACEUTICAL COMPOSITIONS Such combinations, however, are not without their prob AND METHODS OF USE lems. Thus, there still exists a need for novel combinations of CNS active agents and neuromodulators to potentiate the CROSS-REFERENCE TO RELATED pharmacological effect of the CNS active agent, reduce dose APPLICATION dependent side-effects, avoid tolerance/tachyphylaxis prob lems, and overcome the resistance and noncompliance issues. This patent application is a continuation-in-part of Inter More speci?cally, there is a clinical need to develop “non national Application No. PCT/ 1 B2009/ 000309, ?led Feb. 20, sedating” GABA agonists for therapeutic activities where 2009, which is based on and claims the bene?t of US. Pro sedation-related side effect damages the quality of life and visional Patent Application Ser. No. 61/030,141 ?led on Feb. cognitive functioning of the patient, causing the patient to live 20, 2008, the contents of each of which are hereby incorpo most of the day in a daze and making it dangerous to drive rated herein by reference for all that it discloses. vehicles and operate machinery. However, attempts to develop these “non-sedative” benzodiazepines have failed as FIELD OF THE INVENTION the prior art teaches that sedation effects of benzodiazepine The present invention is directed to pharmaceutical com treatment are linked to the GABA-inhibiting therapeutic positions in general, and more particularly to vagal afferent activity. In addition, attempts have been made to develop neuromodulators used in combination with a central nervous non-sedating anxiolytic drugs by chemical modi?cation of system (CNS) active agent as an adjunctive to reduce side the active agent, but no benzodiazepine receptor partial ago effects associated with CNS agent without affecting its thera 20 nist has emerged as a viable alternative. peutic e?icacy. The optimal anxiolytic drug product will be capable of producing a robust anxiolytic action by having a more rapid BACKGROUND onset of action than current therapies while potentially reduc ing the number of side effects. This drug would be compa Various pharmaceuticals, such as CNS active agents cause 25 rable to benzodiazepines, but lacking their limiting side severe side-effects that generally worsen with increasing effects at therapeutic doses. This new drug would represent an doses. Some classes of CNS active agents that require important advancement in the treatment of anxiety disorders. increasing doses include pain reducing drugs, selective sero Even if it is possible that a new, chemically-modi?ed non tonin re-uptake inhibitors, antidepressants, anti-convulsants, sedative GABA agonist may be ?nally developed, there is an hypnotics, anesthetics, sedative agents, angiolytics, NSAIDs, 30 advantage in the utilization of a drug product combination xanthines, antipsychotics, appetite suppressants, sleep from known, approved, and available pharmaceutical ingre agents, antibiotics, antivirals, insulin resistance drugs, anti dients. Such an approach reduces the risk of potential hypertensives, and anti-asthma drugs. At high doses, many unknown toxicity, and the long term development investment CNS active agents rapidly lose their effectiveness, induce required of new pharmaceutical ingredients. pharmacologic tolerance, and cause increasingly severe side 35 In light of the prior art, the inventors surprisingly discov effects. Lowering the dose of the CNS active agent, however, ered that (1) the reduction of sedation-associated side effects does not address the problem because reducing the dose to of CNS active agents is possible using the conventional dos prior levels results in signi?cantly lower therapeutic ef?cacy. age of the CNS drug; (2) chemoreceptor stimulators (i.e. Combinations of centrally active agents have been used in pseudoephedrine (PSE) and other andrenergic receptor ago an effort to overcome the current disadvantages of single 40 nists) optimally reduce the side effects associated with a CNS agent use. In local anesthetic formulations, locally acting agent when a mechanoreceptor stimulator (i.e. guaifenesin adrenergic agonists, such as epinephrine, are known to (GUA)) is administered approximately 15 minutes after enhance the local activity of analgesic drugs and improve administration of the CNS agent and PSE; and (3) adminis therapeutic ef?cacy. For example, it has been demonstrated tration of GUA eliminates the need to use a very high dose of that a higher dosage of epinephrine potentiated the effects of osmoactive polymers (or other osmoactive agents) which can local anesthesia. (Morganroth et al. 2009). Furthermore, sev complicate formulation preparation and disturb the subject’ s eral selective (12 agonist drugs have been used in anesthesia, physiological osmotic balance. either alone or in combination, with various opiate or inhala tional anesthetics, and have been found to reduce the dose SUMMARY OF THE INVENTION requirement for opiates, halothane, or ketamine (Verstegen 50 1989; Nevalainen et al. 1989; Moens and Fargetton 1990). The present invention is directed to pharmaceutical com Additionally, US. Pat. No. 5,605,911 discloses the use of an positions comprising a central nervous system (CNS) active (12 agonist to block the neurotoxic effects, such as hallucina agent and method of use. The compositions and method tions and neuronal damage, of an NMDA antagonist. Simi advantageously reduce a side effect of the CNS active agent. larly, US. Pat. No. 6,562,855 teaches that co-administration 55 In a preferred embodiment, the compositions further com of an NMDA receptor antagonist and an (12 adrenergic ago prise at least two vagal neuromodulators; and a pharmaceu nist both potentiates the effects of anesthesia and diminishes tically-acceptable vehicle, carrier or diluent. The vagal neu the side effects compared to administration of anesthesia romodulators are in an amount suf?cient to reduce a side alone.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • FROM MELANCHOLIA to DEPRESSION a HISTORY of DIAGNOSIS and TREATMENT Thomas A
    1 FROM MELANCHOLIA TO DEPRESSION A HISTORY OF DIAGNOSIS AND TREATMENT Thomas A. Ban International Network for the History of Neuropsychopharmacology 2014 2 From Melancholia to Depression A History of Diagnosis and Treatment1 TABLE OF CONTENTS Introduction 2 Diagnosis and classifications of melancholia and depression 7 From Galen to Robert Burton 7 From Boissier de Sauvages to Karl Kahlbaum 8 From Emil Kraepelin to Karl Leonhard 12 From Adolf Meyer to the DSM-IV 17 Treatment of melancholia and depression 20 From opium to chlorpromazine 21 Monoamine Oxidase Inhibitors 22 Monoamine Re-uptake Inhibitors 24 Antidepressants in clinical use 26 Clinical psychopharmacology of antidepressants 30 Composite Diagnostic Evaluation of Depressive Disorders 32 The CODE System 32 CODE –DD 33 Genetics, neuropsychopharmacology and CODE-DD 36 Conclusions 37 References 37 INTRODUCTION Descriptions of what we now call melancholia or depression can be found in many ancient documents including The Old Testament, The Book of Job, and Homer's Iliad, but there is virtually 1 The text of this E-Book was prepared in 2002 for a presentation in Mexico City. The manuscript was not updated. 3 no reliable information on the frequency of “melancholia” until the mid-20th century (Kaplan and Saddock 1988). Between 1938 and 1955 several reports indicated that the prevalence of depression in the general population was below 1%. Comparing these figures, as shown in table 1, with figures in the 1960s and ‘70s reveals that even the lowest figures in the psychopharmacological era (from the 1960s) are 7 to 10 times greater than the highest figures before the introduction of antidepressant drugs (Silverman 1968).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Clinical Inquiries
    CLINICAL INQUIRIES F ROM THE F AMILY P RACTICE I NQUIRIES N ETWORK What is the best way to evaluate patients with acute diarrhea. Using retrospective 6 acute diarrhea? reviews, Bauer and colleagues developed a pre- diction rule for cases of infectious diarrhea. The “modified 3-day rule” recommends stool cultures EVIDENCE-BASED ANSWER Limited evidence for patients with diarrhea beginning more than 3 delineates the relative probabilities of causes of acute days after hospitalization only when they fall into 1 diarrhea, typically defined as a diarrheal disease last- of the following groups: patients older than 65 ing 14 days or fewer, in the developed world. Viruses years with permanently altered organ function, (rotavirus, Norwalk, and other enteric viruses) are those with HIV or neutropenia, those hospitalized responsible for most cases. Stool culture helps to iden- during suspected nosocomial outbreaks, and those tify bacterial causes (Salmonella, Shigella, enterotoxic suspected of nondiarrheal manifestations of enteric Escherichia coli), especially in patients with fever and infection.6 When the modified rule was applied bloody stool. A modified 3-day rule (eg, performing prospectively, only 2 cases were missed. Both only Clostridium difficile toxin tests on low-risk patients were at risk for immunosuppression, patients who have been hospitalized for 3 or more although they did not strictly meet the modified cri- days) leads to a more rational use of stool cultures teria. Neither required treatment.6 without missing cases of clinically significant disease. (Grade of recommendation: D, based on limited stud- RECOMMENDATIONS FROM OTHERS The ies, reliance on expert opinion, and consensus.) Infectious Diseases Society of America’s practice guidelines for the evaluation and treatment of acute EVIDENCE SUMMARY More than 2 million cases diarrhea recommends that stool culture for bacteria of infectious diarrhea are documented in the United (including enterotoxic E coli) should be considered States annually.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0188539 A1 Harrison Et Al
    US 20080188539A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0188539 A1 Harrison et al. (43) Pub. Date: Aug. 7, 2008 54) RAMPRL-AMNO ACID SALTS 3O Foreigngn AppApplication PrioritVty Data (75) Inventors: Paul Jonathan Harrison, Dublin Dec. 1. 2006 (GB) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - O624084.O (IE); Anna Marie Elizabeth Power, Dublin (IE): Deirdre Publication Classification O'Keeffe, London (GB) (51) Int. Cl. A63L/403 (2006.01) Correspondence Address: C07D 209/02 (2006.01) WILSON SONSIN GOODRCH & ROSAT A6IP3/10 (2006.01) 650 PAGE MILL ROAD A6IP 9/00 (2006.01) PALO ALTO, CA 94304-1050 (US) A6IPI3/2 (2006.01) (52) U.S. Cl. ......................................... 514/412: 548/452 (73) Assignee: Selamine Limited, Dublin (IE) (57) ABSTRACT (21) Appl. No.: 11/948,057 The present invention relates to ramipril-amino acid salts, Such as, naturally occurring, basic amino acid salts of rami (22) Filed: Nov.30, 2007 pril. 1000 2-Theta - Scale Patent Application Publication Aug. 7, 2008 Sheet 1 of 4 US 2008/O188539 A1 s O O O v (SunOO) ul Patent Application Publication Aug. 7, 2008 Sheet 3 of 4 US 2008/O188539 A1 3 e r 6. 76 o 86. co 66.60 3. NE cd O2 42.Eg-s s s CN 98.35sC6-5as, NJE gO'9 YEcs 709 : CO'7 707 6 A-SESM -- 8- 87 FSESE; E () 97 d (5 797 3SES lin Lyg-CS3. Elo 3 re vlg-SS O co 3 o 9. O 64 1. EN SAA's C7 | y N O od ce 8-is-E,Cd OO Yi.
    [Show full text]
  • AMERSA) 125 Whipple Street, 3Rd Floor Providence, Rhode Island 02908
    Strategic Plan for Interdisciplinary Faculty Development: Arming the Nation’s Health Professional Workforce for a New Approach to Substance Use Disorders Edited by MARY R. HAACK, PHD, RN, FAAN HOOVER ADGER, JR., MD, MPH Association for Medical Education and Research in Substance Abuse (AMERSA) 125 Whipple Street, 3rd Floor Providence, Rhode Island 02908 For more information: AMERSA Telephone: 401-349-0000 Fax: 877-418-8769 Web Sites: www.amersa.org and www.projectmainstream.net This publication has been produced by the Association for Medical Education and Research in Substance Abuse under a Cooperative Agreement (HRSA-#U78HP00001) with the Bureau of Health Professions, Health Resources and Services Administration (HRSA), in collaboration with the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA). The conclusions and opinions expressed herein are those of the authors and do not necessarily represent the views and policies of HRSA or of SAMHSA. September 2002 TABLE OF CONTENTS Table of Contents............................................................................................................................................................iii Contributors ....................................................................................................................................................................v Acknowledgments .........................................................................................................................................................vii
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Influence of CYP2D6 and CYP2C19 Gene Variants on Antidepressant
    The Pharmacogenomics Journal (2014) 14, 176–181 & 2014 Macmillan Publishers Limited All rights reserved 1470-269X/14 www.nature.com/tpj ORIGINAL ARTICLE Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder EJ Brandl1,2, AK Tiwari1,2, X Zhou2,3, J Deluce2,3, JL Kennedy1,2,DJMu¨ ller1,2,4 and MA Richter1,2,3,4 Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40–60%). Our study is the largest investigation to date (N ¼ 184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P ¼ 0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P ¼ 0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P ¼ 0.056) and of CYP2C19 metabolizer status with response to sertraline (P ¼ 0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes. The Pharmacogenomics Journal (2014) 14, 176–181; doi:10.1038/tpj.2013.12; published online 2 April 2013 Keywords: obsessive-compulsive disorder (OCD); pharmacogenetics; CYP2D6; CYP2C19; treatment response INTRODUCTION OCD is widely accepted as having strong genetic influence, with Obsessive-compulsive disorder (OCD) occurs in approximately two replicated findings reported for the glutamate transporter gene percent of the population1 and is characterized by a broad variety SLC1A1 and several serotonergic, dopaminergic and other 11 of obsessions and/or compulsions causing significant distress for candidate genes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]